

Geeniregulatsioon ja signaaliülekanne närvisüsteemis ja selle patoloogiates

Tõnis Timmusk
Keemia ja biotehnoloogia instituut
Tallinna Tehnikaülikool

Eesti teaduste akadeemia 24.10.2023


BIOGRAPHICAL SKETCH

NAME Timmusk, Tõnis		POSITION TITLE Professor of Molecular Biology	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Tartu	M.Sc.	06/1982	Biology: cytology and genetics
Karolinska Institute	Ph.D.	06/1994	Molecular neurobiology
Karolinska Institute	Postdoctoral	11/1996	Molecular neurobiology


Positions and Employment

1996-1999	Research Assistant Professor, Department of Neuroscience, Uppsala University, Sweden
1999-2003	Senior Research Scientist. Institute of Biotechnology. University of Helsinki. Finland
2003-2008	Wellcome Trust International Senior Research Fellow, National Institute of Chemical Physics and Biophysics and Department of Gene Technology, Tallinn University of Technology, Estonia
2003 - 2017	Professor, Chair of Molecular Biology, Department of Gene Technology, Tallinn University of Technology, Estonia
2017 - present	Professor of Molecular Biology, Department of Chemistry and Biotechnology, Tallinn University of Technology, Estonia

Molekulaarbioloogia – mis see on?




Molekulaarbioloogia dogma (lihtsustus)



Crick &
Watson, 1956

Närvisüsteem

- kesknärvisüsteem
 - peaaju
 - seljaaju
- perifeerne närvisüsteem
 - närvid
 - perifeersed ganglionid
- enteerne närvisüsteem
 - paikneb seedeelundkonnas
 - võib töötada sõltumatult kesknärvisüsteemist




Närvikoe rakud

Neuronid ehk närvirakud - elektriliselt erutuvad rakud


Gliia – mitte-erutuvad rakud

Neuronite arhitektuurne mitmekesisus




<http://www.mind.ilstu.edu>

väikeaju Purkinje neuron



wikipedia


hipokampuse püramidaalneuron




Rick Haganir; www.learner.org

Astrotsüüdid

Aju keerukuse suurenedes suurenevad astrotsüütide..ja suhteline mõõtmed...



Oberheim et al 2012



Nedergaard et al 2012

Neuron

Multipolar interneuron




Figure 23-2a
Molecular Cell Biology, Sixth Edition
© 2008 W. H. Freeman and Company

Aksoni otsas (terminalis) transformeeritakse elektriline signaal keemiliseks






Figure 23-4a
Molecular Cell Biology, Sixth Edition
© 2008 W. H. Freeman and Company


Neurotroofne hüpotees




Neurotrofiinid ja nende retseptorid



Sünapsite ja rakutuuma kahe-suunaline kommunikatsioon vahendab neuraalseid arengut ja plastilisust



Mutatsioonid sünapside funktsioneerimises osalevates geenides põhjustavad kognitiivsete häiretega närvisüsteemi haigusi




Neurotroofsed tegurid ja närvisüsteemi haigused

Häired neurotroofsete faktorite funktsioonis arvatakse olevat paljude närvisüsteemi haiguste aluseks

- Neurodegeneratiivsed haigused
- Meeleolu- ja ärevushäired
- Perifeersed neuropaatiad
- Seljaaju traumad
- Rasvumine



Neurodegeneratiivsed häred ja neurotroofsed tegurid

BDNF Nucleus caudatus and putamen




- Zuccato et al *Science* 2001
- Zuccato et al *Nature Genetics* 2003
- Kannike et al *J. Biol. Chem.* 2014
- Nurm et al *eNeuro* 2021

NGF, BDNF hippocampus and cerebral cortex





- Kumar et al., *Neuron* 2023



GDNF, NRTN, BDNF, **CDNF**

substantia nigra





6-OHDA GDNF **CDNF**

- Lindholm et al., *Nature*, 2007

GDNF, BDNF

spinal cord




normal

ALS

Stephen
Hawking

- Trupp et al., *J Cell Biol* 1995

BDNF ja depressioon



Olulisemad uuringud/projektid I

1. Neurotrofiin BDNF geeni regulatsiooni mehhanismide väljaselgitamine

(Timmusk et al *Neuron* 1994, *J Cell Biol* 1995, *J Biol Chem* 1999, Palm et al *J Neurosci* 1998; Shieh et al *Neuron* 1998; Pruunsild et al *J Neurosci* 2011; Tuvikene et al *J Neurosci* 2016, Esvald et al *J Neurosci* 2020, 2022; Tuvikene et al *eLife* 2020; Koppel et al *Glia* 2018; Avarlaid et al *Glia* 2023; *Lekk* et al *J Biol Chem* 2023)

2. Närvisüsteemi traumad ja närvirakkude regeneratsiooni molekulaarsed alused

(Funakoshi et al., *J Cell Biol* 1993, *PNAS* 1998; Lauren et al., *Genomics* 2003, *Mol Cell Neurosci* 2003)

3. Huntingtoni tõve molekulaarsete aluste uuringud

(Zuccato et al *Science* 2001; *Nature Genetics* 2003; Kannike et al *J. Biol. Chem.* 2014; Nurm et al *eNeuro* 2021)

4. Neurotrofiin BDNF ja Alzheimeri tõbi

(Kumar et al., *Neuron* 2023)

Olulisemad uuringud/projektid II

5. Uued neurotroofsed tegurid ja nende kasutamine **Parkinsoni tõves** surevate neuronite elushoidmisel

(Trupp et al., *J Cell Biol* 1995; Lindholm et al., *Nature* 2007; Lindholm et al., *Mol Cell Neurosci* 2008)

6. Neurotrofiinide retseptorite antagonistid kui potentsiaalsed **valuvaigistid**

(Tammiku--Taul et al *Eur J Med Chem* 2016)

7. **Skisofreenia ja intellektuaalse puudega** seotud geenid ja nende regulatsioon

(Francks et al *Mol Psych* 2007; Sepp et al., *Plos One* 2011, *Hum Mol Genet* 2012, *J Neurosci* 2017; Karis et al., *Front Mol Neurosci* 2018; Sirp et al *J Biol Chem* 2021; Tamberg et al Biol Open 2015, *Dis Mod Mech* 2020; Sirp et al *Front Mol Neurosci* 2022)

8. **Fuchs'i sarvkesta düstroofiat** põhjustava TCF4 geeni mutatsioonide uuringud

(Sirp et al *Sci Rep* 2020)

Neurotrofiin BDNF: neuronite ellujäämise/surma, sünapsite plastilisuse, õppimise ja mälu molekulaarne alus

Neuron, Vol. 10, 475–489, March, 1993, Copyright © 1993 by Cell Press

Multiple Promoters Direct Tissue-Specific Expression of the Rat BDNF Gene

**Tõnis Timmusk,^{*,†} Kaia Palm,[†] Madis Metsis,^{*,†}
Tõnu Reintam,[‡] Viuu Paalme,[‡] Mart Saarma,[†]
and Håkan Persson^{*}**



^{*}Department of Medical Chemistry (II)
Laboratory of Molecular Neurobiology
Karolinska Institute
Stockholm S-104 01
Sweden

[†]Institute of Biotechnology
University of Helsinki
Helsinki SF-00380
Finland

[‡]Laboratory of Molecular Genetics
Institute of Chemical Physics and Biophysics
Tallinn EE0026
Estonia

rotrophic factor that supports peripheral sympathetic and neural crest-derived sensory neurons as well as central cholinergic neurons (Levi-Montalcini, 1987). Based on this sequence similarity, additional members of a family of structurally related genes coding for neurotrophin-3 (Ernfors et al., 1990a; Hohn et al., 1990; Jones and Reichardt, 1990; Kaisho et al., 1990; Maisonpierre et al., 1990b; Rosenthal et al., 1990) and neurotrophin-4 (Hallböök et al., 1991; Ip et al., 1992), also named neurotrophin-5 (Berkemeier et al., 1991), have been isolated. All four neurotrophins are synthesized as preproteins of similar sizes that are proteolytically cleaved to release the mature neurotrophins, which comprise essentially the 120 carboxy-terminal amino acids of each precursor. In agreement with their important role in the vertebrate nervous

Transcription factors involved in neuronal-activity regulated expression of BDNF gene



RESEARCH ARTICLE

An 840 kb distant upstream enhancer is a crucial regulator of catecholamine-dependent expression of the *Bdnf* gene in astrocytes

Annela Avarlaid¹  | Eli-Eelika Esvald^{1,2}  | Indrek Koppel¹  |
Annabel Parkman¹  | Anna Zhuravskaya³  | Eugene V. Makeyev³  |
Jürgen Tuvikene^{1,2}  | Tõnis Timmusk^{1,2} 

¹Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia

²Protobios LLC, Tallinn, Estonia

³Centre for Developmental Neurobiology, King's College London, London, UK

Correspondence

Annela Avarlaid and Tõnis Timmusk, Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia. Email: annela.avarlaid@taltech.ee; tonis.timmusk@taltech.ee

Funding information


Biotechnology and Biological Sciences Research Council, Grant/Award Numbers: BB/R001049/1, BB/V006258/1; Estonian Research Council, Grant/Award Numbers: IUT19-18, PRG805; European Regional Development Fund, Grant/Award Numbers: 2014-2020.4.01.15-0012, ASTRA 2014-2020.4.01.16-0032; HORIZON EUROPE

Abstract

Brain-derived neurotrophic factor (BDNF) plays a fundamental role in the developing and adult nervous system, contributing to neuronal survival, differentiation, and synaptic plasticity. Dysregulation of BDNF synthesis, secretion or signaling has been associated with many neurodevelopmental, neuropsychiatric, and neurodegenerative disorders. Although the transcriptional regulation of the *Bdnf* gene has been extensively studied in neurons, less is known about the regulation and function of BDNF in non-neuronal cells. The most abundant type of non-neuronal cells in the brain, astrocytes, express BDNF in response to catecholamines. However, genetic elements responsible for this regulation have not been identified. Here, we investigated four potential *Bdnf* enhancer regions and based on reporter gene assays, CRISPR/Cas9 engineering and CAPTURE-3C-sequencing we conclude that a region 840 kb upstream of the *Bdnf* gene regulates catecholamine-dependent expression of *Bdnf* in rodent astrocytes. We also provide evidence that this regulation is mediated by CREB and AP1 family transcription factors. This is the first report of an enhancer coordinating the transcription of *Bdnf* gene in non-neuronal cells.

2-Deoxyglucose drives plasticity via an adaptive ER stress-ATF4 pathway and elicits stroke recovery and Alzheimer's resilience

Graphical abstract



Authors

Amit Kumar,
Saravanan S. Karuppagounder,
Yingxin Chen, ..., Tönis Timmusk,
Daniel H. Geschwind, Rajiv R. Ratan

Correspondence

rrr2001@med.cornell.edu

In brief

Intermittent fasting (IF) is a nutritional paradigm that forestalls cognitive aging, stroke disability, and Alzheimer's progression. How glucose restriction, an aspect of IF, contributes to IF-induced benefits is unclear. Here, we used 2-deoxyglucose to elucidate how low glucose engages an evolutionarily conserved ER stress response pathway to stimulate brain plasticity and treat stroke and AD.


Highlights

- 2-deoxyglucose (2-DG), a glucose-restriction mimetic, drives *Bdnf* transcription
- 2-DG reduces disability after ischemic stroke and improves cognition in AD
- 2-DG inhibits N-glycosylation to induce ER stress, ATF4, and *Bdnf* transcription
- N-glycosylation senses low glucose to drive adaptation to stroke and AD

Kumar et al., 2023, *Neuron* 111, 2831–2846
September 20, 2023 © 2023 Elsevier Inc.
<https://doi.org/10.1016/j.neuron.2023.06.013>

Geenide sisselülitamist kontrolliv valk TCF4/E2-2 ja selle seos vaimse alaarengu ja skisofreeniaga

E47: RERRMANNARERVRVDINEAFRELGRMCQHLKSDKAQTKLLILQQAVQVILGLEQQ
 TCF4: KERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQ
 :*****:*****:***** *:*****.*****:*** **.*****



- Avaldunud paljudes kudedes, kõige rohkem närvisüsteemis
- Klass I bHLH ehk E-valk, seondub E-boksile (CANNTG)
- Heterosügootsed deletsioonid või mutatsioonid põhjustavad **Pitt-Hopkins'i Sündroomi**, (PTHS), mis on arenguline närvisüsteemi haigus, millega kaasneb vaimne alaareng, mikrotsefaalia, epilepsia.
- Ühenukleotiidne polümorfism TCF4 geenis on seotud suurenenud **skisofreenia ja depressiooni** riskiga. No 2 top skisofreenia geen (GWAS)! Leitud ka mutatsioonid skisofreenia patsientides.

Sepp M., Kannike K., Eesmaa A., Urb M., **Timmusk T.** *PLoS ONE*, 2011, 6, e22138.

Sepp M., Pruunsild P., **Timmusk T.** *Hum. Mol. Genet.*, 2012, 21, 2873-2888.

Tamberg L., Sepp M., **Timmusk T.**, Palgi M. *Biol. Open*, 2015, 4, 1762-1771.

Tamberg L., Jaago M., Säälük K., Sirp A., Tuvikene J., Shubina A., Kiir C. S., Nurm K., Sepp M., **Timmusk T.**, Palgi M.. *Dis Model Mech*, 2020, 13: dmm042747.

Sirp A., Roots K., Nurm K., Tuvikene J., Sepp M. **Timmusk T.** *J. Biol. Chem.*, 2021, 297, 101381.

The Intellectual Disability and Schizophrenia Associated Transcription Factor TCF4 Is Regulated by Neuronal Activity and Protein Kinase A

 Mari Sepp,¹ Hanna Vihma,^{1*} Kaja Nurm,^{1*} Mari Urb,^{1*} Stephanie Cerceo Page,² Kaisa Roots,¹ Anu Hark,¹

 Brady J. Maher,^{2,3,4}  Priit Pruunsild,¹ and Tõnis Timmusk¹

¹Department of Chemistry and Biotechnology, Tallinn University of Technology, 12618 Tallinn, Estonia, ²Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland 21205, and ³Department of Psychiatry and Behavioral Sciences and ⁴Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland 21205

Transcription factor 4 (TCF4 also known as ITF2 or E2-2) is a basic helix-loop-helix (bHLH) protein associated with Pitt–Hopkins syndrome, intellectual disability, and schizophrenia (SCZ). Here, we show that TCF4-dependent transcription in cortical neurons cultured from embryonic rats of both sexes is induced by neuronal activity via soluble adenylyl cyclase and protein kinase A (PKA) signaling. PKA phosphorylates TCF4 directly and a PKA phosphorylation site in TCF4 is necessary for its transcriptional activity in cultured neurons and in the developing brain *in vivo*. We also demonstrate that *Gadd45g* (growth arrest and DNA damage inducible gamma) is a direct target of neuronal-activity-induced, TCF4-dependent transcriptional regulation and that TCF4 missense variations identified in SCZ patients alter the transcriptional activity of TCF4 in neurons. This study identifies a new role for TCF4 as a neuronal-activity-regulated transcription factor, offering a novel perspective on the association of TCF4 with cognitive disorders.

Key words: bHLH; E2-2; ITF2; neuronal activity; Pitt–Hopkins syndrome; schizophrenia

Significance Statement

The importance of the basic helix-loop-helix transcription factor transcription factor 4 (TCF4) in the nervous system is underlined by its association with common and rare cognitive disorders. In the current study, we show that TCF4-controlled transcription in primary cortical neurons is induced by neuronal activity and protein kinase A. Our results support the hypotheses that dysregulation of neuronal-activity-dependent signaling plays a significant part in the etiology of neuropsychiatric and neurodevelopmental disorders.

Olulisemad publikatsioonid

- Timmusk T., et al. Multiple promoters direct tissue-specific expression of the rat BDNF gene. *Neuron*, 1993.
- Palm K., et al. Neuronal expression of zinc finger transcription factor REST/NRSF/XBR gene. *J. Neurosci.*, 1998.
- Zuccato, C., et al. Loss of Huntingtin-Mediated BDNF gene transcription in Huntington's disease. *Science*, 2001.
- Lindholm P., et al. Novel neurotrophic factor CDFN protects and rescues midbrain dopamine neurons *in vivo*. *Nature*, 2007.
- Pruunsild P., et al. Identification of *cis*-elements and transcription factors regulating neuronal activity-dependent transcription of human *BDNF* gene. *J. Neurosci*, 2011.
- Tuvikene J., et al. AP-1 transcription factors mediate BDNF-positive feedback loop in cortical neurons. *J. Neurosci.*, 2016.
- Sepp M., et al. The intellectual disability and schizophrenia associated transcription factor TCF4 is regulated by neuronal activity and protein kinase A. *J. Neurosci*, 2017.
- Esvald E.E., et al. CREB family transcription factors are major mediators of BDNF transcriptional autoregulation in cortical neurons. *J. Neurosci*, 2020.
- Tuvikene J., et al. Intronic enhancer region governs transcript-specific BDNF expression in neurons. *eLife*, 2021.
- Avarlaid A., et al. An 840 kb distant upstream enhancer is a crucial regulator of catecholamine-dependent expression of the *Bdnf* gene in astrocytes. *Glia*, 2023.
- Kumar A., et al., 2-Deoxyglucose drives plasticity via an adaptive ER stress-ATF4 pathway and elicits stroke recovery and Alzheimer's resilience. *Neuron*, 2023.

Patentsed leiutised

1. Patentne leiutis: Compounds related to or derived from GFRalpha and their use; Autorid: Mart Saarma, **Tõnis Timmusk**, Matti Airaksinen, Dmitri Poteriaev, Maria Lindahl, Jari Rossi; Prioriteedinumber: FI20000000394; Prioriteedikuupäev: 21.02.2000.
2. Patentne leiutis: Mammalian neuralized family transcriptional regulators and uses; Autorid: Kaia Palm, **Tõnis Timmusk**; Prioriteedinumber: US20010808387; Prioriteedikuupäev: 14.03.2001.
3. Patentne leiutis: Novel neurotrophic factor protein and uses thereof; Autorid: Mart Saarma, **Tõnis Timmusk**, Juha Lauren, Päivi Lindholm, Raimo Tuominen; Prioriteedinumber: US20020406927P; US20030648361; Prioriteedikuupäev: 30.08.2002.
4. Patentne leiutis: Transgenic mouse and cell models and their uses for identification of drugs targeting brain-derived neurotrophic factor; Autorid: **Tõnis Timmusk**, Indrek Koppel, Mari Sepp, Kaur Jaanson, Tamara Aid, Priit Pruunsild, Kaia Palm; Prioriteedinumber: US61/168,319; Prioriteedikuupäev: 10.04.2009
5. Patentne leiutis: Cis- and trans-regulators of BDNF gene and their uses; Owner: Tallinn University of Technology ; Authors: Priit Pruunsild, Mari Sepp, Ester Orav, Indrek Koppel, **Tõnis Timmusk**; Prioriteedi number: US61/456,930; Prioriteedi kuupäev: 15.11.2010.
6. Patentne leiutis: Indole-like TRK receptor antagonists; Omanikud: Tallinna Tehnikaülikool, Tartu Ülikool; Autorid: **Tõnis Timmusk**, Margus Lopp, Eero Vasar, Allen Kaasik, Mati Karelson; Prioriteedi number: US15/249,390; Prioriteedi kuupäev: 27.08.2016.